Skip to main content
SpringerLink
Log in

Schwerpunkt myeloische Neoplasien

Risikoadaptierte Therapie chronischer BCR-ABL1-negativer MPN*

  • Schwerpunkt
  • Published:
InFo Hämatologie + Onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Verwendete Literatur

  1. Mead AJ, Mullally A. Myeloproliferative neoplasm stem cells. Blood. 2017;129(12):1607-16

  2. Zoi K, Cross NC. Genomics of Myeloproliferative Neoplasms. J Clin Oncol. 2017;35(9):947-54

  3. Koschmieder S et al. Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both. Leukemia. 2016;30(5):1018-24

  4. Mesa RA et al. Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: Findings from the MPN Landmark survey. Cancer. 2017;123(3):449-58

  5. Arber DA et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-405

  6. Tefferi A et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014;124(16):2507-13; quiz 2615

  7. Barbui T et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018;32(5):1057-1069

  8. Landolfi R et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004;350(2):114-24

  9. Barbui T et al. Evidence- and consensus-based recommendations for phlebotomy in polycythemia vera. Leukemia. 2018;32(9):2077-81

  10. Heidel FH et al. Questions arising on phlebotomy in polycythemia vera: prophylactic measures to reduce thromboembolic events require patient-focused decisions. Leukemia. 2018;32(9):2085-7

  11. Kiladjian JJ et al. High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood. 2006;108(6):2037-40

  12. Gisslinger H et al. Evidence for Superior Efficacy and Disease Modification after Three Years of Prospective Randomized Controlled Treatment of Polycythemia Vera Patients with Ropeginterferon Alfa-2b Vs. HU/BAT. Blood. 2018;132(Suppl_1):579

  13. Vannucchi AM et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372(5):426-35

  14. Petrides PE et al. Essentielle (oder primäre) Thrombozythämie (ET) Onkopedia - Leitlinien der DGHO. DGHO Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie e. V. 2018. Berlin; https://www.onkopedia.com/de/onkopedia/guidelines/essentielle-oder-primaere-thrombozythaemie-et abgerufen am 7. November 2019

  15. Barbui T et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood. 2012;120(26):5128-33; quiz 5252

  16. Alvarez-Larrán A et al. Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea. Haematologica. 2017;102(1):103-109

  17. Harrison CN et al. Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide. Blood. 2017;130(17):1889-97

  18. Verstovsek S et al. Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results. Blood. 2017;130(15):1768-71

  19. Griesshammer M et al. Contemporary management of patients with BCR-ABL1-negative myeloproliferative neoplasms during pregnancy. Expert Rev Hematol. 2018;11(9):697-706

  20. Griesshammer M et al. Primäre Myelofibrose (PMF) Onkopedia - Leitlinien der DGHO. DGHO Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie e. V. 2018. Berlin https://www.onkopedia.com/de/onkopedia/guidelines/primaere-myelofibrose-pmf abgerufen am 7. November 2019

  21. Guglielmelli P et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study. Blood. 2014;123(14):2157-60

  22. Gangat N et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29(4):392-7

  23. Passamonti F et al. Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. Blood. 2010;116(15):2857-8

  24. Guglielmelli P et al. MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis. J Clin Oncol. 2018;36(4):310-8

  25. Mesa RA et al. Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic. Cancer. 2006;107(2):361-70

  26. Stegelmann F et al. Combination Therapy of Pomalidomide Plus Ruxolitinib in Myelofibrosis: Results From Cohort 1 Of The MPNSG-0212 Trial (NCT01644110) Haematologica. 2017;102 (s2):P700

Download references

Author information

Authors and Affiliations

  1. Jena, Germany

    Florian H. Heidel

  2. Ulm, Germany

    Konstanze Döhner

Authors
  1. Florian H. Heidel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Konstanze Döhner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Florian H. Heidel.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Heidel, F., Döhner, K. Risikoadaptierte Therapie chronischer BCR-ABL1-negativer MPN*. Info Onkol. 22, 21–29 (2019). https://doi.org/10.1007/s15004-019-7223-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15004-019-7223-4

Search

Navigation